Unlocking Precision and Minimizing Morbidity: Sentinel Lymph Node Mapping in Gynecological Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 433
Special Issue Editor
Special Issue Information
Dear Colleagues,
Sentinel lymph node (SLN) mapping has revolutionized the assessment and management of gynecological cancer by providing crucial prognostic information while minimizing treatment-related morbidity. SLN biopsy has transformed the traditional lymph node evaluation paradigm for early stage vulvar, cervical, and endometrial cancers, where nodal status carries significant prognostic implications. With the goal of removing the primary tumor and accurately staging regional lymph nodes, SLN biopsy offers a promising alternative to extensive lymphadenectomies, which are often associated with substantial morbidity.
For vulvar cancer, level 3 evidence supports the safety of omitting inguinofemoral lymphadenectomy when the sentinel node is negative.
Similarly, for clinical early stage endometrial and cervical cancer, acceptable false-negative rates have been observed, indicating the potential clinical utility and safety of SLN biopsy. But despite its potential in these malignancies, SLN biopsy alone has yet to attain gold-standard status due to the lack of prospective evidence on long-term oncological safety. Ongoing prospective trials are expected to shed light on these unresolved issues, providing crucial insights into the efficacy and safety of SLN biopsy.
SLN is not yet an established and widely accepted procedure in ovarian cancer, and evidence of SLN in early EOC is still scarce. Emerging techniques utilizing infundibulopelvic and proper ovarian ligament injections show promise for successful SLN detection during minimally invasive surgeries.
Sentinel lymph node mapping holds immense potential in gynecological cancer care, offering precision staging with reduced morbidity. As ongoing trials continue to investigate its long-term oncological safety, we anticipate that SLN mapping will become an integral component of the standard of care, improving outcomes and enhancing the quality of life for women facing gynecological malignancies.
Dr. Petra L.M. Zusterzeel
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- sentinel lymph node
- gynecological cancer
- vulvar cancer
- endometrial cancer
- cervical cancer
- ovarian cancer
